Sangamo BioSciences | SGMO - Sales Revenues


Sangamo BioSciences reported $356K in Sales Revenues for its fiscal quarter ending in June of 2024.





Sales Change Date
Alaunos Therapeutics USD 2K 2K Mar/2025
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Amgen USD 8.62B 1.28B Mar/2026
Bayer EUR 13.41B 1.97B Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Biogen USD 2.25B 30M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Cipla INR 71.19B 5.78B Jun/2026
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 6.35M 60.98M Mar/2026
CSL USD 8.33B 4.79B Dec/2025
Gilead Sciences USD 7B 930M Mar/2026
GlaxoSmithKline GBP 7.63B 991M Mar/2026
Grifols EUR 2B 306.7M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
J&J USD 25.31B 1.21B Jun/2026
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Merck USD 16.29B 110M Mar/2026
Novartis USD 14.41B 1.3B Jun/2026
Pfizer USD 14.5B 3.08B Mar/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.24B 60M Mar/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Tectonic Therapeutic USD 0 0 Dec/2024
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026